Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-azacitidine and Gemtuzumab Ozogamicin in Relapsed AML
NCT00766116Phase 2Completed
- Sponsor
- University of California, San Diego
- Start
- Jul 2005
- Primary completion
- Sep 2014
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of azacitidine and gemtuzumab ozogamicin in acute myeloid leukemia (AML) (4 arms), sponsored by University of California, San Diego. Primary endpoint: Number of Participants With Dose Limiting Toxicities at 28 days. Started Jul 2005; status: completed.
02
Drugs
azacitidinegemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00766116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00766116.